Search

Displaying results 1441 - 1450 of 7498 in total
  1. Drug

    Betaine

    go.drugbank.com/drugs/DB06756
    ApprovedInvestigationalNutraceutical

    Currently, no treatments are available to correct the genetic causes of homocystinuria. … [L43105] Although it is present in many food products, the levels found there are insufficient to treat this condition.

    Mixtures: Neo Life Beta Gest TabSynonyms: 2-N,N,N-trimethylammonio acetate, N,N,N-Trimethylglycine
  2. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    Atopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.

  3. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017. … [L40054] Axicabtagene ciloleucel was later approved by the EMA on August 23, 2018.[L42090]

  4. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal. … [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  5. Drug

    Mazindol

    go.drugbank.com/drugs/DB00579
    Approved

    Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than [amphetamine], but with some similar side effects. … It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). … [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein.

  7. Drug

    N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

    go.drugbank.com/drugs/DB11202
    Approved

    N-alkyl ethylbenzyl dimethyl ammonium (c12-c14) is a quaternary ammonium compound with surfactant properties. … C12-C14 dimethyl ethylbenzyl ammonium chloride is difficult to elucidate.

    Salts: N-alkyl ethylbenzyl dimethyl ammonium chloride (C12-C14)Mixtures: Mevon No. 72 Liq
  8. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. … It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.

  9. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003] … [A232563] These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.

  10. Drug

    Methacholine

    go.drugbank.com/drugs/DB06709
    Approved

    [A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763] … [A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M<sub>3</sub> muscarinic receptors that stimulate ASM contraction